Navigation Links
D-Pharm (TASE: DPRM) Announces Enrollment of First Patient in DP-b99 Phase III Efficacy Study, MACSI
Date:12/31/2009

REHOVOT, Israel, December 31 /PRNewswire-FirstCall/ -- D-Pharm Ltd (TASE: DPRM) announced enrollment of patients with acute ischemic stroke into its Phase III clinical study of DP-b99 (MACSI). The first patient has been enrolled at the Wolfson Medical Center, Israel. The MACSI trial involves numerous medical centers in the US, Canada, Europe, Israel, South Africa, South Korea and Brazil. DP-b99 is D-Pharm's most advanced product developed for protection of brain cells suffering from restricted blood and oxygen supply (ischemia).

The MACSI study is as international, multicenter, randomized, double-blind, placebo-controlled Phase III clinical trial. The trial will compare the stroke outcome in a group of patients treated with placebo (an inactive substance) to patients treated with 1 mg/kg/day of DP-b99 for 4 consecutive days. The study is expected to enroll, in total, 770 patients at 120 - 140 clinical sites worldwide.

Recently D-Pharm met with the FDA to discuss the Special Protocol Assessment (SPA) and will continue the dialog with the FDA towards the final agreement.

Dr. Gilad Rosenberg, D-Pharm's V.P. Clinical Development stated, "We're very pleased that this important clinical milestone has been achieved on schedule. The challenge is now to effectively activate the additional clinical sites to ensure a patient recruitment rate sufficient to complete the study on time, as planned."

For the global development of DP-b99, D-Pharm Ltd. will collaborate with its partners Yungjin Pharmaceuticals in S. Korea and Wanbang Biopharmaceuticals in China. Stroke is a leading cause of serious long-term disability and the second most common cause of death worldwide. The number of acute ischemic stroke patients in the US, Western Europe and Japan is around 1.5 million; including the territories of S. Korea and China may almost double this figure.

About DP-b99


'/>"/>

SOURCE D-Pharm Ltd
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. D-Pharm Completes Pre-IND Meeting With the FDA for Treatment of Acute Stroke With DP-b99
2. D-Pharm Secures Funding From Israels Chief Scientists Office
3. D-Pharm Receives FDA Clearance to Commence a Phase III Trial of DP-b99 in Acute Stroke Patients
4. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
5. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
6. Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering
7. BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.
8. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
9. China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results
10. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
11. Advanced Life Sciences Announces Receipt of Nasdaq Staff Letter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/6/2015)... , March 6, 2015   InspireMD, Inc. (NYSE ... protection systems, announced today that it will release its full ... 31, 2014 on Thursday, March 12 th after market ... to review its financial results and business outlook. ... ) or (412) 542-4135 (International) and request the InspireMD call. ...
(Date:3/6/2015)... , March 6, 2015 BioSpecifics Technologies ... developing first in class collagenase-based products marketed as XIAFLEX ... U.S. and XIAPEX ®  in the EU, announced today ... audio webcast at 8:30 a.m. ET on Friday, March ... year 2014 financial results and provide a corporate update. ...
(Date:3/6/2015)... March 6, 2015 ... 2011 von der Assistance Publique - Hôpitaux ... Sie ist eine französische, gemeinschaftliche, randomisierte Kontrollstudie ... rekrutiert wurden. Verglichen werden Patienten mit fortgeschrittenem ... Harz-Mikrosphären oder Sorafenib behandelt wurden. Die Ergebnisse ...
(Date:3/5/2015)... 05, 2015 Plant disease specialists from ... at the Annual Meeting of The American Phytopathological Society. ... released online now at APSnet.org/meet . , The ... meeting, to be held August 1-5, 2015 in Pasadena, ... Field Trips, Workshops, and committee meetings, all carefully balanced ...
Breaking Biology Technology:InspireMD to Report Financial Results for the Fourth Quarter and Year Ended December 31, 2014 on Thursday, March 12th 2BioSpecifics Technologies Corp. to Host Conference Call to Report Fourth Quarter and Full Year 2014 Financial Results on Friday, March 13, 2015 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 2Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 3Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 4Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 5Behandlung von primärem Leberkrebs: SARAH-Studie schließt Rekrutierung ab, Ergebnisse werden für Ende 2016 erwartet 6American Phytopathological Society Announces Annual Meeting Daily Schedule 2
... 15, 2010 Ocera Therapeutics, Inc. announced today ... safety and pharmacokinetics of OCR-002 (ornithine phenylacetate) which ...  OCR-002 recently received Orphan Drug status and Fast ... Drug Administration for the treatment of hyperammonemia (excessive ...
... brain-machine interface designed to help paralyzed subjects move objects with ... arm providing sensory feedback, a new study from the University ... into the movement of a computer cursor or an external ... these early systems, vision was the only tool a subject ...
... 2010 The Association for Career and Technical Education ... Role in Worker Retraining" that describes how career and ... adults and providing them the skills needed to re-enter the ... not only focus on local employment needs, but are also ...
Cached Biology Technology:Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy 2Ocera Therapeutics Completes First in Human Studies with OCR-002 for the Treatment of Hyperammonemia and Hepatic Encephalopathy 3Robot arm improves performance of brain-controlled device 2Robot arm improves performance of brain-controlled device 3ACTE Releases Issue Brief Outlining Critical Role CTE Plays in Worker Retraining 2
(Date:2/5/2015)... 2015  It is gratifying to see that the ... genomic science as a means to better understand human ... I was honored to participate in today,s White House ... Since the 1980s my teams have ... first sequenced genome of a free living organism, the ...
(Date:1/22/2015)... /PRNewswire/ - Today, FindBiometrics, the leading source of biometrics industry news, ... website design. "When we launched FindBiometrics 12 years ... O,Neill , founder and CEO of FindBiometrics. "Now it,s maturing ... the key players on a very broad scale.  We are ...
(Date:1/22/2015)...  A man-made form of insulin delivered by nasal spray ... adults with mild cognitive impairment and Alzheimer,s disease dementia, ... Wake Forest Baptist Medical Center. The study,s ... impairment (MCI) or mild to moderate Alzheimer,s dementia (AD). ...
Breaking Biology News(10 mins):J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3
... forms far deeper than geologists previously thought, according to new ... of Rice University put very small samples of peridotite, rock ... The scientists found that the rock can and does ... those found as deep as 250 kilometers down in the ...
... conditions lead to what kinds of bacterial infections? If doctors ... pre-treatment with certain kinds of antibiotics. A University of Colorado ... International Journal of Infectious Diseases shows the answer: ... especially prevalent in patients with lung and GI cancers, more ...
... Kan. -- A competitive grant is helping a Kansas ... spreading one of the worst plant diseases into a ... Badillo-Vargas, a plant pathology doctoral student, Puerto Rico, recently ... $71,000 from the U.S. Department of Agriculture,s National Institute ...
Cached Biology News:Magma in Earth's mantle forms deeper than once thought 2Magma in Earth's mantle forms deeper than once thought 3Planning for bacteria in cancer patients may help hospitals fight infections 2USDA grant advancing deadly plant disease, insect research 2
... The product contains 5 ml of ... to release mouse CD4+ T cells from ... isolated mosue CD4+ T cells from Dynabeads ... isolated cells are suitable for any downstream ...
Porcine IFN-gamma ELISpot Development Module...
...
Request Info...
Biology Products: